Auto-injector (AI)

DEVICE3 trials

Sponsors

Genentech, Inc., Eli Lilly and Company

Conditions

HealthyHealthy Volunteers

Phase 1

A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

CompletedNCT02996019

Genentech, Inc.Healthy Volunteers

Start: 2016-12-07End: 2018-04-09Updated: 2018-12-03

A Study of Two Formulations of LY3074828 in Healthy Participants

CompletedNCT03662100

Eli Lilly and CompanyHealthy

Start: 2018-09-06End: 2019-01-25Updated: 2024-01-25

A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

CompletedNCT04004988

Eli Lilly and CompanyHealthy

Start: 2019-08-19End: 2019-12-16Updated: 2023-04-18

Related Papers

Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers

Advances in Therapy2021-03-293 citations

An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers

Advances in Therapy2021-03-29